Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New appointment at MDS Pharma Services

This article was originally published in Scrip

Executive Summary

MDS Pharma Services (US) has appointed Dr Ross Tonkens as vice-president of medical affairs, to provide medical oversight for the company's Phase IIa clinical research activities and to direct the medical and clinical activities of its development and regulatory services business. Dr Tonkens will design clinical study protocols, provide medical consultation to clients and chair the company's development and regulatory services medical advisory board. In addition, he will represent MDS Pharma Services and serve as the 2008 chair of the ethics and clinical practice committee of the Association of Clinical Research Organizations (ACRO). Before joining MDS, Dr Tonkens was chief medical officer of the Duke University biotechnology spin-off Regado Biosciences, and was global head of cardiovascular therapeutics at Quintiles.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC003278

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel